Imatinib Mesylate

• 

  Subject Areas on Research

  • A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. 
  • A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. 
  • A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. 
  • A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. 
  • A validated LC method for imatinib mesylate. 
  • Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages. 
  • Abl family kinases regulate endothelial barrier function in vitro and in mice. 
  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. 
  • Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass. 
  • Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. 
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. 
  • BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients. 
  • Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. 
  • Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. 
  • Chronic myelogenous leukemia. 
  • Clinical and in vitro studies of imatinib in advanced carcinoid tumors. 
  • Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. 
  • Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. 
  • Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. 
  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. 
  • Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. 
  • Defective T cell development and function in the absence of Abelson kinases. 
  • Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. 
  • Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells. 
  • E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells. 
  • Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. 
  • Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. 
  • Fatal hepatic necrosis following imatinib mesylate therapy. 
  • Gastrointestinal stromal tumors, version 2.2014. 
  • Gleevec, an Abl family inhibitor, produces a profound change in cell shape and migration. 
  • Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. 
  • Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. 
  • Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. 
  • Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia. 
  • Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. 
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. 
  • Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. 
  • Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. 
  • Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. 
  • Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. 
  • Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia. 
  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. 
  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. 
  • Neurofibromatosis type 2. 
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. 
  • Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 
  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. 
  • Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. 
  • Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 
  • Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. 
  • Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. 
  • Platelet-derived growth factor receptors: a therapeutic target in solid tumors. 
  • Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction. 
  • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. 
  • Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. 
  • Requirement for Abl kinases in T cell receptor signaling. 
  • Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. 
  • SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. 
  • Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. 
  • Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. 
  • Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. 
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. 
  • The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. 
  • The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML). 
  • The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. 
  • Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. 
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. 
  • Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients. 
  • Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. 
  • Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. 
  • When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia. 
  • ZIP kinase, a key regulator of myosin protein phosphatase 1. 
  • β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.